When topicals aren’t enough, but biologics feel like a step too far, some patients are left without another option.1-4
Peptides are highly specific, binding directly to targets (eg, receptors or ligands) to help achieve their intended benefits and limit off-target effects. They’re not small molecules, but they’re not as large as antibodies—so could they be JUST RIGHT?5,6

Know the science
See how targeted oral peptide technology could help strike a balance in dermatology7,8
References: 1. Lebwohl M, Langley RG, Paul C, et al. Dermatol Ther (Heidelb). 2022;12(1):61-78. doi:10.1007/s13555-021-00635-4 2. Armstrong AW, Bohannan B, Mburu S, et al. Dermatology. 2023;239(4):621-634. doi:10.1159/000528945 3. Wollenberg A, Gooderham M, Katoh N, et al. Arch Dermatol Res. 2024;316(7):380. doi:10.1007/s00403-024-03130-w 4. Wan V, Habibi A, Abdi P, Mukovozov I, Asiniwasis RN, Maibach HI. Australas J Dermatol. 2024;65(4):387-389. doi:10.1111/ajd.14243 5. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. doi:10.1016/j.drudis.2014.10.003 6. Purohit K, Reddy N, Sunna A. Exploring the potential of bioactive peptides: from natural sources to therapeutics. Int J Mol Sci. 2024;25(3):1391. doi:10.3390/ijms25031391 7. Xiao W, Jiang W, Chen Z, et al. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025;10(1):74. doi:10.1038/s41392-024-02107-5 8. Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? J Med Chem. 2018;61(4):1382-1414. doi:10.1021/acs.jmedchem.7b00318